Mankind Pharma Q1 FY27 Results: Standalone Revenue ₹2,964 Crore, Consolidated Revenue ₹4,030 Crore
Mankind Pharma reported standalone revenue of ₹2,964 crore and consolidated revenue of ₹4,030 crore for the quarter ended June 30, 2026. The company approved issuing a corporate guarantee for its subsidiary BSV and the sale of its stake in Broadway Hospitality Services for ₹49 crore.
The financial results indicate a stable performance. The corporate guarantee and divestment are significant strategic decisions that could impact future operations and financial structure.
The company reported positive financial results for the quarter, with growth in both standalone and consolidated revenues. The approval of a corporate guarantee and a divestment agreement also indicate strategic business activities.
Mankind Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors, in their meeting held on July 30, 2026, approved these results.
On a standalone basis, the company reported revenue from operations of ₹2,964.05 crore and other income of ₹33.96 crore, leading to a total income of ₹2,998.01 crore. Expenses amounted to ₹2,241.44 crore, resulting in a profit before tax of ₹756.57 crore. After tax expenses of ₹198.08 crore, the net profit for the quarter stood at ₹558.49 crore. Total comprehensive income after tax was ₹552.49 crore.
The consolidated financial results for the same period showed revenue from operations at ₹4,030.59 crore and other income of ₹45.00 crore, bringing the total income to ₹4,075.59 crore. Total expenses were ₹3,310.08 crore. Profit before tax was ₹769.45 crore, and after tax expenses of ₹195.36 crore, the net profit attributable to equity holders of the parent was ₹554.35 crore. Total comprehensive income attributable to equity holders of the parent was ₹582.87 crore.
The company also approved the issuance of a corporate guarantee in favor of Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary. Separately, the company completed the execution of a Share Purchase Agreement on July 27, 2026, for the sale of its 100% stake in Broadway Hospitality Services Private Limited for a cash consideration of ₹49 crore, subject to closing adjustments. A certificate from Joint Statutory Auditors under Regulation 54 of the Listing Regulations for the quarter ended June 30, 2026, was also enclosed.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.